Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk...
PRINCETON, N.J.--(BUSINESS WIRE)--Dec 10, 2023--
PRINCETON, N.J.--(BUSINESS WIRE)--Dec 10, 2023--